DUPILUMAB

DUPILUMAB (12291X)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
12291X
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Initial treatment of the whole body

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Continuing or resuming treatment of the whole body

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Initial treatment of the face and/or hands

Restriction

Indication: Chronic severe atopic dermatitis
Treatment phase: Continuing or resuming treatment of the face and/or hands
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,755.99 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (12309W)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
12309W
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment 1 - (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 8 DPMQ: $1,609.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (12313C)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
12313C
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment 1 - (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 8 DPMQ: $1,658.74 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (12316F)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
12316F
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,658.74 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (12318H)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
12318H
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Continuing treatment
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,609.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (14961K)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
14961K
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy), Initial treatment - Initial 2 (Change of treatment), Continuing treatment, or transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements - Balance of Supply in a patient aged 6 to 12 years
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 0 DPMQ: $1,609.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (14977G)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
14977G
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy), Initial treatment - Initial 2 (Change of treatment), Continuing treatment, or transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements - Balance of Supply in a patient aged 6 to 12 years
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 0 DPMQ: $1,658.74 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (14999K)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
14999K
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 7 DPMQ: $1,658.74 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (15021N)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
15021N
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Continuing treatment

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 5 DPMQ: $1,609.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent

DUPILUMAB (15041P)

dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes
15041P
Body System:
Manner of administration:Injection
Public
S100 HSD Public
Authority Required

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 1 (New patient; or Recommencement of treatment in a new treatment cycle following a break in PBS-subsidised biological medicine therapy)

Restriction

Indication: Uncontrolled severe asthma
Treatment phase: Initial treatment - Initial 2 (Change of treatment)
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 7 DPMQ: $1,609.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Dupixent